SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2016 - 2015 - 2014 - 2013

September 2016 Scleroderma News

Factors relating to impaired stroke volume during the 6–minute walk test in patients with systemic sclerosis. Impaired stroke volume in patients with systemic sclerosis was observed at rest and during exercise, and the factors relating to the cardiac response seemed to be pulmonary function and the extent of pulmonary hypertension. PubMed, Clin Exp Rheumatol, 07/22/2016. (Also see Pulmonary Hypertension Diagnosis and Diagnosis of Scleroderma Pulmonary Involvement)

Examination of the association of sex and race/ethnicity with appearance concerns: a Scleroderma (SSc) Patient–centered Intervention Network (SPIN) Cohort study. Appearance concerns were common in SSc and women were substantially more likely than men to have appearance concerns. PubMed, Clin Exp Rheumatol, 08/01/2016. (Also see Quality of Life with Scleroderma)

Esophageal dilatation and interstitial lung disease in systemic sclerosis (SSc): A cross-sectional study. Increasing esophageal diameter on high–resolution computed tomography in patients with SSc is associated with more severe radiographic interstitial lung disease, lower lung volumes, and lower DLCO % predicted. PubMed, Semin Arthritis Rheum, 2016 Aug;46(1):109-14. (Also see Pulmonary Fibrosis and Esophageal (Throat) Involvement)

Outcome of a glucocorticoid (GC) discontinuation regimen in patients with inactive systemic sclerosis. Disability as assessed by Health Assessment Questionnaire Disability Index (HAQ–DI) was the leading factor hindering GC discontinuation, as a low HAQ–DI score can identify candidates for GC discontinuation. PubMed, Clin Rheumatol, 2016 Aug;35(8):1985-91. (Also see Glucocorticoids, Steroids (Prednisone) Warnings for Scleroderma)

The protective effect of hydrogen sulfide (H2S) on systemic sclerosis associated skin and lung fibrosis in mice model. We demonstrate the beneficial effects of H2S on SSc–associated skin and lung fibrosis. H2S may be a potential therapy against this intractable disease. PubMed, Springerplus, 2016 Jul 15;5(1):1084. (Also see Scleroderma Clinical Trials)

Rare Case of Diffuse Scleroderma Triggered by Cancer Chemotherapy. A woman with metastatic colorectal cancer treated with the chemotherapy drug Xeloda (capecitabine) developed diffuse scleroderma – a condition never before linked to the use of this particular cancer drug. Scleroderma News, 08/11/2016. (Also see Cancer and Scleroderma)

Gender differences in systemic sclerosis (SSc): relationship to clinical features, serologic status and outcomes. Gender differences may be important clues to understanding the natural history and pathogenesis of SSc. Journal of Scleroderma and Related Disorders, JSRD 2016; 1(2): 204 - 212. (Also see Hormones and Chromosomes in Scleroderma)

Systemic sclerosis (SSc) –related calcinosis. SSc–related calcinosis has received very little attention in terms of research into pathogenesis, measurement, and treatment and although we still do not have an effective treatment, progress is being made. Journal of Scleroderma and Related Disorders, JSRD 2016; 1(2): 194 - 203. (Also see Calcinosis)

Extracorporeal shock wave therapy (ESWT) for digital ulcers associated with systemic sclerosis (SSc). The results of our study suggest that ESWT has the potential to be a novel and efficacious treatment for digital ulcers associated with SSc, and can be added to pharmacological therapy. Journal of Scleroderma and Related Disorders, JSRD 2016; 1(2): 181 - 185. (Also see Treatments for Digital Ulcers in Scleroderma)

Systemic sclerosis (SSc) trial design moving forward. This article highlights recent advances in research methodology, and broadens the potential range of design and analytic considerations when planning an SSc trial. Journal of Scleroderma and Related Disorders, JSRD 2016; 1(2): 177 - 180. (Also see Scleroderma Clinical Trials)

Go to Scleroderma Medical News: August 2016
 
Recent Donors
See ISN News for recent donors, including memorials for
Patricia Ann Black, Gayle Hedlin, and Janet Paulmenn.
 

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

 
The most important thing in the world to know about scleroderma is sclero.org!
Donate Now
Copyright 1998-2016, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.